Tenofovir Disoproxil Fumarate Treatment for Pediatric Patients with Perinatally Acquired Chronic Hepatitis B
Journal Title: Gastro - Open Journal - Year 2015, Vol 1, Issue 4
Abstract
Objectives: Infection with Hepatitis B Virus (HBV) is an important cause of chronic liver disease in children. Perinatal transmission accounts for the majority of infections. We examined the effects of Tenofovir Disoproxil Fumarate (TDF) on pediatric patients with perinatally acquired Chronic Hepatitis B (CHB). Methods: We retrospectively analyzed the data on pediatric patients with perinatally acquired CHB treated with TDF over a 72-week period. Results: 55 cases were analyzed of which 26 were treated. Fourteen (54%) had immune active hepatitis and 12(46%) were in the immune tolerant phase. In both groups, no difference in inflammation or fibrosis was found on baseline liver biopsy. Mean HBV DNA level at baseline was 9 log10 copies/mL. Levels declined to 5.9 log10 copies/mL at 40 weeks of therapy and were undetectable in 19/26(73%) of the patients by week 72. Alanine aminotransferase (ALT) levels normalized by 32 weeks in the immune active hepatitis group. No breakthrough elevations were seen in either group. Overall, 11(42%) and 9(35%) of the patients had Hepatitis B e antigen (HBeAg) clearance and Hepatitis B e antibody (anti-HBe) seroconversion respectively by 72 weeks of treatment. Conclusion: TDF is an effective therapy in pediatric patients with perinatally acquired CHB in both immune active hepatitis and immune tolerant phase patients. Response to treatment did not seem to be affected by baseline ALT levels and liver histopathology findings.
Authors and Affiliations
Ricardo A. Arbizu
Keywords
Related Articles
- EP ID EP555808
- DOI 10.17140/GOJ-1-116
- Views 148
- Downloads 0
Salvage Cryotherapy for Treatment of Persistent Barrett’s Esophagus
Background: A dysplastic Barrett’s esophagus can lead to cancer if not treated by endoscopic eradication therapy. The current consensus is to eradicate the entire residual Barrett’s esophagus that is visible during endos...
Analysis of the Intracellular Zinc in HCV Replicon
Aim: In patients with chronic liver injury, metabolic disturbance of zinc was frequently observed and Hepatitis C virus (HCV) replication is crucially involved with zinc metabolism. In vitro HCV replication system, HCV r...
Therapeutic and Chemopreventive Effects of Ursodeoxycholic Acid (UDCA): Potential Role in Patients with Barrett’s Esophagus
Ursodeoxycholic Acid (UDCA) is widely used for the treatment of cholestatic liver diseases. Major mechanisms of this action are protection of cholangiocytes against cytotoxicity of hydrophobic bile acids, stimulation of...
Management of Inflammatory Bowel Diseases in Jehovah’s Witness
Background: Treatment of Inflammatory Bowel Disease (IBD) patients who are known to be Jehovah’s Witness (JW) can be a unique challenge. JW accept most available medical treatments, but may not accept blood transfusions...
Robot-Assisted Minimally Invasive McKeown Esophagectomy with a Four-Arm Platform: Technique and Early Experience
Objectives: We report an early, single-institution experience of Robot-Assisted Minimally Invasive McKeown Esophagectomy (RAMIME) using a four-arm platform. The technique details, rationale, complications, and pitfalls d...